Transcriptomic data from a gallbladder cancer cell line with acquired chemoresistance to gemcitabine [NOZ]

Gallbladder cancer (GBC) has few therapeutic options, being gemcitabine the first-line chemotherapeutic drug. However, this treatment shows poor clinical outcomes on patients. The acquired resistance phenomenon during of the treatment is one of the main factors that leads to insufficient therapeutic effects, and the molecular mechanisms carried out by tumor cells against gemcitabine are still poorly understood. First, we established a GBC cell line with acquired resistance to gemcitabine (NOZ GemR) from parental cell line (NOZ). After, we used microarray hybridization in NOZ and NOZ GemR to characterize their transcriptional profile to identify differentially expressed genes and/or molecular pathways involved chemoresistant cell phenotype. NOZ, a GBC cell line sensitive to gemcitabine, was subjected to increasing concentrations of gemcitabine for six months until obtaining a cell subline with stable acquired resistance against gemcitabine (NOZ GemR). Then, total RNA extracted and purified from NOZ and NOZ GemR was analyzed by Affymetrix microarray to study the mRNA expression levels in both conditions. Differentially expressed genes were identified in NOZ GemR respect to NOZ to elucidate the transcriptional networks underlying gemcitabine resistance in GBC cells. Three independent replicates for each sample were used.